Characterization of sensitivity and resistance mechanisms to DHX9 inhibitor in endometrial and ovarian cancer cell lines
RNA-seq (gene expression) · human · 48 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Ovarian cancerThis series is part of our curated briefing on it.
- Samples
- 48 samples: 16 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE316734_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1404100 and SRA study SRP663471. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 48 samples.
How we read this: 16 replicated groups read from 48 sample titles; they account for 48 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9459112 AN3CA_DMSO_rep 1 AN3CA_DMSO
- GSM9459113 AN3CA_DMSO_rep 2 AN3CA_DMSO
- GSM9459114 AN3CA_DMSO_rep 3 AN3CA_DMSO
- GSM9459115 AN3CA_DHX9i_rep 1 AN3CA_DHX9i
- GSM9459116 AN3CA_DHX9i_rep 2 AN3CA_DHX9i
- GSM9459117 AN3CA_DHX9i_rep 3 AN3CA_DHX9i
- GSM9459118 MFE296_DMSO_rep 1 MFE296_DMSO
- GSM9459119 MFE296_DMSO_rep 2 MFE296_DMSO
- GSM9459120 MFE296_DMSO_rep 3 MFE296_DMSO
- GSM9459121 MFE296_DHX9i_rep 1 MFE296_DHX9i
- GSM9459122 MFE296_DHX9i_rep 2 MFE296_DHX9i
- GSM9459123 MFE296_DHX9i_rep 3 MFE296_DHX9i
- GSM9459124 KLE_DMSO_rep 1 KLE_DMSO
- GSM9459125 KLE_DMSO_rep 2 KLE_DMSO
- GSM9459126 KLE_DMSO_rep 3 KLE_DMSO
- GSM9459127 KLE_DHX9i_rep 1 KLE_DHX9i
- GSM9459128 KLE_DHX9i_rep 2 KLE_DHX9i
- GSM9459129 KLE_DHX9i_rep 3 KLE_DHX9i
- GSM9459130 MFE280_DMSO_rep 1 MFE280_DMSO
- GSM9459131 MFE280_DMSO_rep 2 MFE280_DMSO
- GSM9459132 MFE280_DMSO_rep 3 MFE280_DMSO
- GSM9459133 MFE280_DHX9i_rep 1 MFE280_DHX9i
- GSM9459134 MFE280_DHX9i_rep 2 MFE280_DHX9i
- GSM9459135 MFE280_DHX9i_rep 3 MFE280_DHX9i
- GSM9459136 ARK2_DMSO_rep 1 ARK2_DMSO
- GSM9459137 ARK2_DMSO_rep 2 ARK2_DMSO
- GSM9459138 ARK2_DMSO_rep 3 ARK2_DMSO
- GSM9459139 ARK2_DHX9i_rep 1 ARK2_DHX9i
- GSM9459140 ARK2_DHX9i_rep 2 ARK2_DHX9i
- GSM9459141 ARK2_DHX9i_rep 3 ARK2_DHX9i
- GSM9459142 OVCAR3_DMSO_rep 1 OVCAR3_DMSO
- GSM9459143 OVCAR3_DMSO_rep 2 OVCAR3_DMSO
- GSM9459144 OVCAR3_DMSO_rep 3 OVCAR3_DMSO
- GSM9459145 OVCAR3_DHX9i_rep 1 OVCAR3_DHX9i
- GSM9459146 OVCAR3_DHX9i_rep 2 OVCAR3_DHX9i
- GSM9459147 OVCAR3_DHX9i_rep 3 OVCAR3_DHX9i
- GSM9459148 PEO4_DMSO_rep 1 PEO4_DMSO
- GSM9459149 PEO4_DMSO_rep 2 PEO4_DMSO
- GSM9459150 PEO4_DMSO_rep 3 PEO4_DMSO
- GSM9459151 PEO4_DHX9i_rep 1 PEO4_DHX9i
+ 8 more — browse all 48 samples with per-sample file links →
- GSE314300 Rb CUT&RUN profiling in ovarian cancer cell lines following CDK2 inhibitor treatment 10 samples same disease briefing · shares inhibitor, ovarian, lines
- GSE311212 Transcriptomic profiling in human ovarian cancer cell line OVCAR-3 following CDK2 inhibitor treatment 6 samples same disease briefing · shares inhibitor, ovarian
- GSE135242 Hi-C identifies structural variation associated with resistance in paired patient-derived ovarian cancer models 8 samples same disease briefing · shares resistance, ovarian
- GSE268514 Integrative genomic analysis of Korean high-grade serous ovarian cancer 161 samples same disease briefing · shares ovarian
- GSE128098 TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2α as a therapeutic target 4 samples same disease briefing · shares ovarian
- GSE154600 Multi-omic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma 5 samples same disease briefing · shares ovarian
- GSE57477 Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes 72 samples same disease briefing · shares ovarian
- GSE28330 Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents 107 samples same disease briefing · shares sensitivity
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.